Tags

Type your tag names separated by a space and hit enter

Dose-response effect of an intra-tendon application of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in a rat Achilles tendinopathy model.
J Orthop Res. 2013 Mar; 31(3):413-20.JO

Abstract

The purpose of this study was to assess whether intra-tendon delivery of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) would improve Achilles tendon repair in a rat collagenase-induced tendinopathy model. Seven days following collagenase induction of tendinopathy, one of four intra-tendinous treatments was administered: (i) Vehicle control (sodium acetate buffer), (ii) 1.02 µg rhPDGF-BB, (iii) 10.2 µg rhPDGF-BB, or (iv) 102 µg rhPDGF-BB. Treated tendons were assessed for histopathological (e.g., proliferation, tendon thickness, collagen fiber density/orientation) and biomechanical (e.g., maximum load-to-failure and stiffness) outcomes. By 7 days post-treatment, there was a significant increase in cell proliferation with the 10.2 and 102 µg rhPDGF-BB-treated groups (p=0.049 and 0.015, respectively) and in thickness at the tendon midsubstance in the 10.2 µg of rhPDGF-BB group (p=0.005), compared to controls. All groups had equivalent outcomes by Day 21. There was a dose-dependent effect on the maximum load-to-failure, with no significant difference in the 1.02 and 102 µg rhPDGF-BB doses but the 10.2 µg rhPDGF-BB group had a significant increase in load-to-failure at 7 (p=0.003) and 21 days (p=0.019) compared to controls. The rhPDGF-BB treatment resulted in a dose-dependent, transient increase in cell proliferation and sustained improvement in biomechanical properties in a rat Achilles tendinopathy model, demonstrating the potential of rhPDGF-BB treatment in a tendinopathy application. Consequently, in this model, data suggest that rhPDGF-BB treatment is an effective therapy and thus, may be an option for clinical applications to treat tendinopathy.

Authors+Show Affiliations

Sports Medicine, BioMimetic Therapeutics, Inc., 389 Nichol Mill Lane, Franklin, Tennessee, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22933269

Citation

Shah, Vivek, et al. "Dose-response Effect of an Intra-tendon Application of Recombinant Human Platelet-derived Growth factor-BB (rhPDGF-BB) in a Rat Achilles Tendinopathy Model." Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society, vol. 31, no. 3, 2013, pp. 413-20.
Shah V, Bendele A, Dines JS, et al. Dose-response effect of an intra-tendon application of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in a rat Achilles tendinopathy model. J Orthop Res. 2013;31(3):413-20.
Shah, V., Bendele, A., Dines, J. S., Kestler, H. K., Hollinger, J. O., Chahine, N. O., & Hee, C. K. (2013). Dose-response effect of an intra-tendon application of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in a rat Achilles tendinopathy model. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society, 31(3), 413-20. https://doi.org/10.1002/jor.22222
Shah V, et al. Dose-response Effect of an Intra-tendon Application of Recombinant Human Platelet-derived Growth factor-BB (rhPDGF-BB) in a Rat Achilles Tendinopathy Model. J Orthop Res. 2013;31(3):413-20. PubMed PMID: 22933269.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dose-response effect of an intra-tendon application of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in a rat Achilles tendinopathy model. AU - Shah,Vivek, AU - Bendele,Alison, AU - Dines,Joshua S, AU - Kestler,Hans K, AU - Hollinger,Jeffrey O, AU - Chahine,Nadeen O, AU - Hee,Christopher K, Y1 - 2012/08/29/ PY - 2012/03/29/received PY - 2012/08/07/accepted PY - 2012/8/31/entrez PY - 2012/8/31/pubmed PY - 2013/3/27/medline SP - 413 EP - 20 JF - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JO - J. Orthop. Res. VL - 31 IS - 3 N2 - The purpose of this study was to assess whether intra-tendon delivery of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) would improve Achilles tendon repair in a rat collagenase-induced tendinopathy model. Seven days following collagenase induction of tendinopathy, one of four intra-tendinous treatments was administered: (i) Vehicle control (sodium acetate buffer), (ii) 1.02 µg rhPDGF-BB, (iii) 10.2 µg rhPDGF-BB, or (iv) 102 µg rhPDGF-BB. Treated tendons were assessed for histopathological (e.g., proliferation, tendon thickness, collagen fiber density/orientation) and biomechanical (e.g., maximum load-to-failure and stiffness) outcomes. By 7 days post-treatment, there was a significant increase in cell proliferation with the 10.2 and 102 µg rhPDGF-BB-treated groups (p=0.049 and 0.015, respectively) and in thickness at the tendon midsubstance in the 10.2 µg of rhPDGF-BB group (p=0.005), compared to controls. All groups had equivalent outcomes by Day 21. There was a dose-dependent effect on the maximum load-to-failure, with no significant difference in the 1.02 and 102 µg rhPDGF-BB doses but the 10.2 µg rhPDGF-BB group had a significant increase in load-to-failure at 7 (p=0.003) and 21 days (p=0.019) compared to controls. The rhPDGF-BB treatment resulted in a dose-dependent, transient increase in cell proliferation and sustained improvement in biomechanical properties in a rat Achilles tendinopathy model, demonstrating the potential of rhPDGF-BB treatment in a tendinopathy application. Consequently, in this model, data suggest that rhPDGF-BB treatment is an effective therapy and thus, may be an option for clinical applications to treat tendinopathy. SN - 1554-527X UR - https://www.unboundmedicine.com/medline/citation/22933269/Dose_response_effect_of_an_intra_tendon_application_of_recombinant_human_platelet_derived_growth_factor_BB__rhPDGF_BB__in_a_rat_Achilles_tendinopathy_model_ L2 - https://doi.org/10.1002/jor.22222 DB - PRIME DP - Unbound Medicine ER -